Longboard Pharmaceuticals (LBPH) Revenue & Revenue Breakdown
Longboard Pharmaceuticals Revenue Highlights
Longboard Pharmaceuticals Revenue by Period
Longboard Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | - |
Longboard Pharmaceuticals generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Longboard Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $8.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Longboard Pharmaceuticals generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Longboard Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| MNOV | MediciNova | $1.00M | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| DSGN | Design Therapeutics | - | - |
| CCCC | C4 Therapeutics | - | - |
| LBPH | Longboard Pharmaceuticals | - | - |
| NXTC | NextCure | - | - |
| DBTX | Decibel Therapeutics | - | - |
| TIL | Instil Bio | - | - |
| GRPH | LENZ Therapeutics | - | - |
| CYT | Cyteir Therapeutics | - | - |
| CELC | Celcuity | - | - |
| SNSE | Sensei Biotherapeutics | - | - |
| MACK | Merrimack Pharmaceuticals | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
| NUVB | Nuvation Bio | - | $1.44M |
| CSBR | Champions Oncology | - | - |
LBPH Revenue FAQ
What is Longboard Pharmaceuticals’s yearly revenue?
Longboard Pharmaceuticals's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. LBPH's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Longboard Pharmaceuticals’s quarterly revenue?
Longboard Pharmaceuticals's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). LBPH's quarterly revenue for Q4 2023 was $8K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Longboard Pharmaceuticals’s revenue growth rate?
Longboard Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 0%